Sugi Predict

Sugi Predict / Compounds / SCHEMBL91050

SCHEMBL91050

SCHEMBL91050

OC[C@H]1O[C@@H](n2cnc3c(Cl)ncnc32)C(O)C1O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 7/20 0.73
▸ STAT6 P42226 2/20 0.73
▸ DPP4 P27487 1/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ SLC28A1 O00337 1/20 0.73
▸ MAP3K7 O43318 1/20 0.73
▸ SLC28A2 O43868 1/20 0.73
▸ GAPDH P04406 1/20 0.73
▸ ADORA3 P0DMS8 1/20 0.73
▸ MAPK1 P28482 1/20 0.73
▸ ADORA2A P29274 1/20 0.73
▸ ADORA2B P29275 1/20 0.73
▸ ADORA1 P30542 1/20 0.73
▸ PI4KA P42356 1/20 0.73
▸ KMT2A Q03164 1/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ PI4K2B Q8TCG2 1/20 0.73
▸ DOT1L Q8TEK3 1/20 0.73
▸ PI4K2A Q9BTU6 1/20 0.73
▸ SLC28A3 Q9HAS3 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL272122 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL1858029 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL19443159 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL319667 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL278513 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL67126 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL10062644 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL272123 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL10340725 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1
SCHEMBL21139429 1.00 SLC29A1 (0.73) SLC29A1STAT6DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022155418-A9 MODIFIED OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2023-03-09 — — WO disclosed
US-20220380402-A1 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2022-12-01 — — US disclosed
US-10744209-B2 Biodegradable polymeric nanoparticle conjugates and use thereof NEW YORK UNIVERSITY (US) 2020-08-18 — — US disclosed
US-10675293-B2 Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-06-09 — — US disclosed
US-20190315792-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES PHARMASSET, LTD. (BB) 2019-10-17 — — US disclosed
US-10301348-B2 Compounds for use in prevention and treatment of neurodegenerative diseases and pain ACADEMIA SINICA (TW) 2019-05-28 — — US disclosed
US-20180064744-A1 NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-08 — — US disclosed
EP-2498774-B1 DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES ACADEMIA SINICA (TW) 2017-10-11 — — EP disclosed
US-20120295863-A1 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases ACADEMIA SINICA (TW) 2012-11-22 — — US disclosed
US-20120245335-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES GILEAD PHARMASSET LLC (US) 2012-09-27 — — US disclosed
EP-2345661-A1 Modified fluorinated nucleoside analogues Pharmasset, Inc. (US) 2011-07-20 — — EP disclosed
EP-2345659-A1 Modified fluorinated nucleoside analogues Pharmasset, Inc. (US) 2011-07-20 — — EP disclosed
US-20110165564-A1 SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-07-07 — — US disclosed
US-20110038833-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES PHARMASSET, INC. (US) 2011-02-17 — — US disclosed
US-20090036666-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES PHARMASSET, INC. (US) 2009-02-05 — — US disclosed
US-20090004135-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES PHARMASSET, INC. (US) 2009-01-01 — — US disclosed
US-7429572-B2 Modified fluorinated nucleoside analogues PHARMASSET, INC. (US) 2008-09-30 — — US disclosed
US-20080221060-A1 Adenosine derivatives for treatment of pain and/or inflammation; diabetes BIOVITRUM AB (PUBL) (SE) 2008-09-11 — — US disclosed
US-20080176816-A1 Method of making and using an adenosine analogue ACADEMIA SINICA 2008-07-24 — — US disclosed
US-20080070861-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES PHARMASSET, INC. (US) 2008-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070861-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES NSUN2, NT5C3B, METTL3 SLC29A1 9/4885STAT6 1941/4885DPP4 1803/4885
US-20080221060-A1 Adenosine derivatives for treatment of pain and/or inflammation; diabetes ADORA3, ADORA2B, P2RX3 SLC29A1 1087/4885STAT6 1388/4885DPP4 1013/4885
US-20080176816-A1 Method of making and using an adenosine analogue HTT, ADA, GDA SLC29A1 38/4885STAT6 4750/4885DPP4 397/4885
US-20180064744-A1 NUCLEOSIDE AGENTS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES NSUN2, RNGTT, ADAR SLC29A1 141/4885STAT6 4128/4885DPP4 3510/4885
US-10301348-B2 Compounds for use in prevention and treatment of neurodegenerative diseases and pain ADORA2A, ADORA3, ADORA2B SLC29A1 340/4885STAT6 2858/4885DPP4 1010/4885
US-20090036666-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES NSUN2, NT5C3B, METTL3 SLC29A1 9/4885STAT6 1941/4885DPP4 1803/4885
US-20190315792-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES NSUN2, NT5C3B, METTL3 SLC29A1 9/4885STAT6 1941/4885DPP4 1803/4885
US-20110038833-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES NSUN2, NT5C3B, METTL3 SLC29A1 9/4885STAT6 1941/4885DPP4 1803/4885
US-10744209-B2 Biodegradable polymeric nanoparticle conjugates and use thereof CD47, SLC46A1, ABCB1 SLC29A1 388/4885STAT6 4698/4885DPP4 3132/4885
US-20090004135-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES NSUN2, NT5C3B, METTL3 SLC29A1 9/4885STAT6 1941/4885DPP4 1803/4885
US-20120245335-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES NSUN2, NT5C3B, METTL3 SLC29A1 9/4885STAT6 1941/4885DPP4 1803/4885
US-20120295863-A1 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases ADORA2A, ADORA1, ADORA3 SLC29A1 6/4885STAT6 4641/4885DPP4 1291/4885
US-10675293-B2 Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes NSUN2, RNGTT, ADAR SLC29A1 141/4885STAT6 4128/4885DPP4 3510/4885
US-20220380402-A1 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY ADORA2A, ADORA1, ADORA3 SLC29A1 165/4885STAT6 1262/4885DPP4 844/4885
US-20110165564-A1 SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES DNMT1, MAT2B, AHCY SLC29A1 804/4885STAT6 3227/4885DPP4 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.